The Implications of Obesity as a Disability in Europe

Despite rising obesity in Europe, the EU has yet to approve weight loss drugs from Arena (ARNA), Vivus (VVUS), or Orexigen (OREX).

Jul 19, 2014 at 4:13PM

If Europe's top court follows the advice of a key advisor, it may soon label severe obesity as a disability. If it does, pressure may increase in the European Union to approve drugs designed to reduce weight, including compounds developed by Arena Pharmaceuticals (NASDAQ:ARNA), Vivus (NASDAQ:VVUS), and Orexigen (NASDAQ:OREX).


Source: European Parliament Flickr.

Treating obesity
Obesity is a major cause of diabetes (almost 90% of diabetics are overweight) and increasingly thicker waistlines have industry watchers predicting that the number of people with diabetes will soar from 366 million to 552 million globally by 2030 and that the number of people living with the disease in Europe will climb from less than 53 million people to more than 64 million people. That significant increase is expected to spike health-care spending on diabetes, which totaled a combined $120 billion in France, Germany, Italy, Spain, and the U.K. in 2012.

That expected spending surge has the drug industry investing billions to develop new diabetes treatments, but it's not just the industry giants that are developing therapies that may have a profound impact on the disease. Small companies like Arena, Vivus, and Orexigen have developed drugs that may help prevent diabetes by controlling patient weight.


Source: Arena Pharmaceuticals.

A new class of weight-loss drugs
The FDA has already approved two new weight-loss drugs, one from Arena Pharmaceuticals and another from Vivus, but neither has been a hit (yet).

Sales of Arena and marketing partner Eisai's Belviq, totaled just $3 million in the first quarter; however, Eisai recently reported that it's bulking up its U.S. sales force by 50%. That increases the number of people calling on doctors to about 600.

Vivus hasn't done much better with its Qsymia. Qysmia won FDA approval in 2012, but its sales totaled just $9 million in the first quarter.

Europe says not yet
Last year, Arena withdrew its application for Belviq's approval in the European Union after it recognized that it wouldn't be able to address a key advisory panel's questions prior to the panel making a recommendation. Those questions surround Arena's potential side effects and risks, including tumors found in rats treated with the drug during trials.

While Arena and Eisai still hope to win over EU regulators someday, it simply might not happen. Arena openly admits this risk in its quarterly 10-Q filing with the SEC: "We expect Eisai to potentially submit for regulatory approval in Europe at a later date, but Belviq may not be submitted for regulatory approval in Europe when expected or ever." (emphasis added)

Vivus' case for Qsymia has similarly hit roadblocks in Europe. EU regulators rejected Vivus' application and the appeal that followed based on worries that long-term use of Qysmia could result in cardiovascular and central nervous system disease. Vivus has since asked EU regulators whether interim analysis from an ongoing long-term use study could be used as part of a resubmission, and the company appears to be advancing in that direction; but no timing has been offered up as to when such a resubmission may happen.

Although both Arena and Vivus have stalled in Europe, Orexigen may still have a shot at approval there. Orexigen's NB32 weight-loss drug got rejected by the FDA in 2011 due to cardiovascular concerns, prompting Orexigen to launch a cardiovascular outcomes trial in 2012 that delivered positive interim results last year.

Based on those results, Orexigen resubmitted NB32 to FDA regulators in January, and the FDA gave the company an expected decision date in June. However, the FDA pushed that date back until September in order to hash out more details with the company. Regardless, Orexigen should get a decision from both EU and U.S. regulators this year.

Fool-worthy final thoughts
Arena's, Vivus', and Orexigen's drugs mark the first wave of anti-obesity compounds; but other drugs may be coming. For example, Zafgen has an orphan drug called beloranib that has also shown some success in weight loss and, while Zafgen is pursuing an approval for the orphan disease Prader-Willi Syndrome, it may someday seek approval for more generalized weight loss, too.

Whether any of these drugs end up having an impact in Europe, however, remains to be seen. There's little question that obesity is a major reason behind rising diabetes prevalence rates throughout the EU -- Germany boasts the EU's highest prevalence of diabetes cases -- but that doesn't guarantee that fear about rising health-care costs will overcome regulators' concerns about the potential adverse effects of these drugs. 

Leaked: This coming blockbuster will make Arena, Vivus, and Orexigen jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier, and more accurately, than anyone else. Let me cut right to the chase. There's a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns, you'll need The Motley Fool's new free report on the dream team responsible for this game-changing blockbuster. CLICK HERE NOW.

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information